Single and combination antibiotic susceptibilities of planktonic adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis

Journal of Clinical Microbiology

Volumn 40, Issue 11, 2002, Pages 4172-4179

  Aaron, Shawn D ^a   Ferris, Wendy ^a   Ramotar, Karam ^a   Vandemheen, Katherine ^a   Chan, Francis ^a   Saginur, Raphael ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BACTERIUM ISOLATE; BIOFILM; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; MONOLAYER CULTURE; NONHUMAN; PLANKTON; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM CULTURE;

ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BIOFILMS; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0036840718     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.40.11.4172-4179.2002     Document Type: Article

References (35)

1. Aaron, S. D., W. Ferris, D. A. Henry, D. P, Speert, and N. E. MacDonald, 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161:1206-1212.
2. Anderl, J. N., M. S. Franklin, and P. S. Stewart. 2000. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 44:1818-1824.
3. Anwar, H., J. L. Strap, and J. W. Costerton. 1992. Establishment of aging biofilms: Possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob. Agents Chemother. 36:1347-1351.
4. Anwar, H., T. van Biesen, M. Dasgupta, K. Lam, and J. W. Costerton. 1989. Interaction of biofilm bacteria with antibiotics in a novel in vitro chemostat system. Antimicrob. Agents Chemother. 33:1824-1826.
5. Baltimore, R. S., C. D. C. Christie, and G. J. W. Smith. 1989. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Am. Rev. Respir. Dis. 140:1650-1661.
6. Ceri, H., M. E. Olson, C. Stremick, R. R. Read, D. Morck, and A. Buret. 1999. The Calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
7. Cochran, W. L., G. A. McFeters, and P. S. Stewart. 2000. Reduced susceptibility of thin Pseudomonas aeruginosa biofilms to hydrogen peroxide and monochloramine. J. Appl. Microbiol. 88:22-30.
8. Costerton, J. W. 1999. Introduction to biofilm. Int. J. Antimicrob. Agents 11:217-221.
9. Costerton, J. W., K.-J. Cheng, G. G. Geesey, T. I. Ladd, J. C. Nickel, M. Dasgupta, and T. J. Marrie. 1987. Bacterial biofilms in nature and disease. Annu. Rev. Microbiol. 41:435-464.
10. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: A common cause of persistent infections. Science 284:1318-1322.
11. Dahl, M., A. Tybjærg-Hansen, P. Lange, and B. G. Nordestgaard. 1998. ΔF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet 351:1911-1913.
12. Das, J. R., M. Bhakoo, M. V. Jones, and P. Gilbert. 1998. Changes in the biocide susceptibility of Staphylococcus epidermidis and Escherichia coli cells associated with rapid attachment to plastic surfaces. J. Appl. Microbiol. 84:858.
13. Davies, D. G., M. R. Parsek, J. P. Pearson, B. H. Iglewski, J. W. Costerton, and E. P. Greenberg. 1988. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280:295-298.
14. de Beer, D., P. Stoodley, F. Roe, and Z. Lewandowski. 1994. Effects of biofilm structure on oxygene distribution and mass transport. Biotechnol. Bioeng 43:1131-1138.
15. Donlan, R. M. 2000. Role of biofilms in antimicrobial resistance. ASAIO J. 46:S47-S52.
16. Drenkard, E., and F. M. Ausubel. 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740-743.
17. Hancock, R. E. W., and D. P. Speert. 2000. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and impact on treatment. Drug Resist. Updates 3:255.
18. Hoiby, N. 2002. New antimicrobials in the management of cystic fibrosis. J. Antimicrob. Chemother. 49:235-238.
19. Laing, F. P, Y., K, Ramotar, R. R, Read, N. Alfieri, A. Kureishi, E. A. Henderson, and T. J. Louie, 1995. Molecular epidemiology of Xanthomonas mahophilia colonization and infection in the hospital environment. J. Clin. Microbiol. 33:513-518.
20. Lang, B. J., S. D, Aaron, W. Ferris, P. C. Hebert, and N. E, MacDonald, 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 162:2241-2245.
21. Miyake, Y., S. Fujiwara, T, Usul, and H. Suginaka. 1992. Simple method for measuring the antibiotic concentration required to kill adherent bacteria. Chemotherapy 38:286-290.
22. National Committee for Clinical Laboratory Standards. 2001. Method for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved standard M7-AS. NCCLS, Wayne, Pa.
23. O'Toole, G., and R. Kolter. 1998. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 30:295-304.
24. Regelmann, W., G. Elliott, W. Warwick, and C. Clawson. 1990. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cytic fibrosis more than do bronchodilators and chest physiotherapy alone. Am. Rev. Respir. Dis. 141:914-921.
25. Saiman, L., F. Mehar, W. W. Niu, H. C. Neu, K. J. Shaw, G. Miller, and A. Prince. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537.
26. Singh, P. K., A. L. Schaefer, M. R. Parsek, T. O. Moninger, M. J. Welsh, and E. P. Greenberg. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764.
27. Smith, A. L., C. Doershuk, D. Goldmann, E. Gore, B. Hilman, M. Marks, R. Moss, B. Ramsey, G. Redding, T. Rubio, J. Williams-Warren, R. Wilscott, D. Wilson, and R. Yogen. 1999. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J. Pediatr. 134:413-421.
28. Spoering, A. L., and K. Lewis. 2001. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J. Bacteriol. 183:6746-6751.
29. Stewart, P. S. 1996. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob. Agents Chemother. 40:2417-2422.
30. Stewart, P. S., and J. W. Costerton. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
31. Tack, K. J., and L. D. Sabath. 1985. Increased minimum inhibitory concentrations with anaerobiasis for tobramycin, gentamicin, and amikacin, compared to latamoxef, piperacillin, chloramphenicol, and clindamycin. Chemotherapy 31:204-210.
32. Tenover, F. C., R. D. Arbeit, and R. V. Goering. 1995. Interpreting chromosomal DNA restriction patterns produced by pulse-field gel electrophoresis: Criteria for bacterial stain typing. J. Clin. Microbiol. 33:2233-2239.
33. Walter, J., S. Seeney, S. Bell, S. Bowler, P. Masel, and J. McCormack. 2002. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial. Thorax 57:212-216.
34. Williams, I., W. A. Venables, Lloyd D., F. Paul, and I. Critchley. 1997. The effects of adherence to silicone surfaces on antibiotic susceptibility in Staphylococcus aureus. Microbiology 143:2407-2413.
35. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, and P. E. Ochsner. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococal infections. A randomized controlled trial. JAMA 279:1537-1541.